Evidence map›Paper›PMID 20679133›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2010

Comparison between 3-Nitrooxyphenyl acetylsalicylate (NO-ASA) and O2-(acetylsalicyloxymethyl)-1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (NONO-ASA) as safe anti-inflammatory, analgesic, antipyretic, antioxidant prodrugs.

Mitali Chattopadhyay, Carlos A Velazquez, April Pruski, Kamran V Nia, Khaled R Abdellatif, Larry K Keefer, Khosrow Kashfi

Erratum issuedOpen access · bronzeAbstract readComparative Study
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Acetylsalicylic Acid-Primus Inter Pares in Pharmacology.Molecules (Basel, Switzerland) · 2022
    Review
  3. Article
  4. Review
  5. The dichotomous role of HBiochemical pharmacology · 2018
    Review
  6. Prodrugs of NSAIDs: A Review.The open medicinal chemistry journal · 2017
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Nitric Oxide-Releasing Hybrid Drugs Target Cellular Processes Through S-Nitrosylation.Forum on immunopathological diseases and therapeutics · 2012
    Article
  15. Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Mitali ChattopadhyayDepartment of Physiology and Pharmacology, City University of New York Medical School, 138th St. and Convent Ave., New York, NY 10031, USA.
Carlos A Velazquez
April Pruski
Kamran V Nia
Khaled R Abdellatif
Larry K Keefer
Khosrow Kashfi
New York Medical College · USCity University of New York · USUniversity of Alberta · CA

Funding

Using Diazeniumdiolate Chemistry to Design Nitric Oxide-Based TherapiesZIABC005673 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KEEFER, LARRY K · 2009 to 2015
$5.5M
Intramural NIH HHS ZIA BC005673
6 · The paper itself

Abstract

Chronic inflammation is an underlying etiological factor in carcinogenesis; nonsteroidal anti-inflammatory drugs (NSAIDs) and their chemically modified NO-releasing prodrugs (NO-NSAIDs) are promising chemopreventive agents. The aim of this study was to conduct a head-to-head comparison between two NO-ASAs possessing different NO donor groups, an organic nitrate [3-nitrooxyphenyl acetylsalicylate (NO-ASA; NCX-4016)] and an N-diazeniumdiolate [NONO-ASA, O(2)- (acetylsalicyloxymethyl)-1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (NONO-ASA; CVM-01)], as antiulcerogenic, analgesic, anti-inflammatory, and antipyretic agents. All drugs were administered orally at equimolar doses. For antiulcerogenic study, 6 h after administration, the number and size of hemorrhagic lesions in stomachs from euthanized animals were counted. Tissue samples were frozen for prostaglandin E(2) (PGE(2)), superoxide dismutase (SOD), and malondialdehyde determination. For anti-inflammatory study, 1 h after drug administration, the volume of carrageenan-induced rat paw edemas was measured for 6 h. For antipyretic study, 1 h after dosing, fever was induced by intraperitoneal LPS, and body core temperatures measured for 5 h. For analgesic study, time-dependent analgesic effect of prodrugs was evaluated by carrageenan-induced hyperalgesia. Drugs were administered 30 min after carrageenan. NO-ASA and NONO-ASA were equipotent as analgesic and anti-inflammatory agents but were better than aspirin. Despite a drastic reduction of PGE(2) in stomach tissue, both prodrugs were devoid of gastric side effects. Lipid peroxidation induced by aspirin was higher than that observed by prodrugs. SOD activity induced by both prodrugs was similar, but approximately 2-fold higher than that induced by aspirin. CVM-01 is as effective as NCX-4016 in anti-inflammatory, analgesic, and antipyretic assays in vivo, and it showed an equivalent safety profile in the stomach. These results underscore the use of N-diazeniumdiolate moieties in drug design.

Indexed as

AnimalsAnti-Inflammatory Agents, Non-SteroidalAntioxidantsAntipyreticsAspirinDinoprostoneDisease Models, AnimalEdemaFeverGastric MucosaHydrazinesHyperalgesiaLipid PeroxidationMaleMalondialdehydeMolecular StructureAnti-Inflammatory Agents, Non-SteroidalAntioxidantsAntipyreticsAspirinDinoprostoneHydrazinesMalondialdehydenitroaspirinO2-(acetylsalicyloxymethyl)-1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolateProdrugsSuperoxide DismutaseTumor Necrosis Factor-alpha

Identifiers

PMID20679133
PMCPMC2967407
OpenAlexW2021467687

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.